Hannah Scott

I work in at the Nuffield Department of Clinical Medicine (Research Building), in the Target Discovery Institute within the Medical and Life Science Division at the Mass Spectrometry and Life Sciences group (Kessler lab).

My research focusses on metabolomics, lipidomics and ubiquitin biology. My research projects are based on 1. deubiquitylating enzymes (DUBs) and cancer of which ubiquitin specific protease 18 (USP18) is of particular interest, especially its potential role in lipid metabolism 2. inflammation and immunolipids in disease 3. women’s health such as polycystic ovarian syndrome and fibroids targeting the role of USP19 and probing the function of steroid sex hormones in these diseases and 4.) DNA metabolism, specifically nucleosides and nucleotides in cancer.

I use liquid chromatography-ion mobility-quadrupole time of flight mass spectrometry (LC-IM-QTOF) for discovery, identification, accurate mass, and collisional cross section for lipidomics and small molecule analysis. To provide ultra-sensitivity for DNA metabolism and lipidomics, I use a multiple reaction monitoring method utilising a LC-triple quad mass spectrometer (LC-QQQ). Some metabolites that are not ionised using electrospray ionisation and also for acidic lipid investigation I use a two dimensional gas chromatography mass spectrometer (GCxGC-MS) which deploys electron impact ionisation.

As the lead analyst of the LC-QQQ I manage projects and can be contacted for a quote for our use of our facility for small molecule, metabolomics, lipidomics or nucleoside/nucleoside analysis. 

I purchase consumables, chemical reagents, and laboratory equipment for the Kessler group. In addition, I am trained as a fire warden and will soon become a psychological first aider as one of the departments Mental Health Allies.

Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.

USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation.